

Coronavirus Infection Prevention by Wearing Masks

Thi Sinh Vo¹ , Tran Thi Thu Ngoc Vo^{2,3} , Tran Thi Bich Chau Vo⁴ 



ABSTRACT

The coronavirus disease 2019 (COVID-19) [2019-nCoV; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] was first detected in Wuhan, China at the end of 2019. In current status, spread of COVID-19 in person-to-person could be caused mainly by respiratory droplets, which leads to the spread of the influenza virus in both community and clinicians. Thus, in order to reduce the risk of that, the urgent management strategies against COVID-19 are to block transmission, isolation, protection, and using drug or vaccine updated on an ongoing basis. Unfortunately, no drugs or vaccines still have yet been allowed to treat patients with COVID-19, so the rapid detection of effective intercessions against COVID-19 is seemed a major challenge on the all world. Herein, this article attempts summarizing to introduce the characterization of COVID-19, the influence of droplets travel in person-to-person transmission and the effect of wearing masks in the infection prevention of influenza virus, as well as understanding its advantage and role in the coronavirus infection prevention.

Keywords: Coronavirus, COVID-19, Infection prevention of influenza virus, Wearing masks.

Introduction

The coronavirus disease 2019 (COVID-19) outbreak is one of the hot issues around the world today. As known, the influenza virus (influenza A virus subtype H1N1 (H1N1), severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 viruses) outbreak is a threat to human health, as well as a major challenge for both community and clinicians [1-4]. For example, health care workers (HCWs) can initially be at risk and get infected from examining and treating patients with a respiratory infection [5] and then become indiscreet carriers to other patients, family members, and the community if they do not regularly wash their hands or take other infection-preventive measures. In addition, owing to shortages in the availability of antiviral medicine and delays in drug or vaccine development, respiratory protection is one of the key non-pharmaceutical interventions for protection of both community and clinicians. As such, it is truly necessary for each individual in the community and for clinicians to use personal respiratory protective methods to prevent infection of the influenza virus. Therefore, currently, handwashing and wearing masks are one of the ways of preventing infection of the influenza virus. However, currently, there are gaps in the knowledge about the prevention of influenza virus by wearing masks (cloth masks, medical masks, N95 respirators, and surgical masks). Hence, this paper aims to introduce the characteristics of COVID-19, the influence of droplet travel in person-to-person transmission, and the effect of wearing masks in COVID-19 infection prevention.

Characteristics of COVID-19

To date, the emergence and rapid transmission of COVID-19 from patients with severe pneumonia in Wuhan, China, has become a global health concern [6-9]. The features of COVID-19 are similar to those of SARS (or MERS), which is known as a single-stranded RNA b-coronavirus genome with enveloping and positive-sense, ranging from 26 to 32 kilobases in length [10], as well as encoding non-structural, structural, and accessory proteins. Fever, fatigue, and dry cough are considered symptoms of COVID-19. Sometimes, there are a few patients with mild

Cite this article as: T.S. Vo, T.T.N. Vo and T.T.B.C. Vo. Coronavirus Infection Prevention by Wearing Masks. Eurasian J Med 2020; 52(2): 197-201.

¹School of Mechanical Engineering, Sungkyunkwan University, Suwon, Republic of Korea

²Department of Acupuntur, Tuina and Moxibustion, Anhui University of Traditional Chinese Medicine, Anhui, China

³Qui Nhon City Hospital, Binh Dinh, Vietnam

⁴Department of Industrial Management, Can Tho University, Can Tho, Vietnam

Received: March 24, 2020

Accepted: April 9, 2020

Correspondence to: Tran Thi Bich Chau Vo
E-mail: vttbchau@ctu.edu.vn

DOI 10.5152/eurasianjmed.2020.20056



Content of this journal is licensed under a Creative Commons Attribution 4.0 International License.

symptoms and then patients gradually start experiencing aches, nasal congestion, runny nose, sore throat, or diarrhea. Several people who are infected do not develop any symptoms; in particular, older adults and people with underlying medical diseases (diabetes, heart problems, or high blood pressure) are prone to experience serious symptoms, especially those with a history of close contact with COVID-19-infected patients and a history of travel to Wuhan, China. The period of incubation is generally 3–7 days or 14 days [11]. For example, a 65-year-old Chinese man was admitted to Cho Ray Hospital in Ho Chi Minh City, Vietnam [12] and a 35-year-old man was referred to an urgent care clinic in Snohomish, Washington, USA [13], both had cough and fever during the last four days of the incubatory period.

To further understand its characteristics, Huang et al. [9] and Chan et al. [14] showed the multifocal ground-glass changes in the chest and lung computed tomography (CT) scans (Figure 1) that are typical of viral pneumonia. One of the disease development features is the bilateral multiple lobular and sub segmental areas of consolidation found in the chest CT scan. Besides, in CT scan images, the lungs of older patients were further diffused and found to be wider than those of the younger patients [11, 14]. According to some references for the source of the COVID-19 emergence, most of the infected patients were associated with the seafood wholesale market in Wuhan, China [9], or the COVID-19 virus penetrated into the market place before it spread from there [15]; however, the spread of COVID-19 remains largely unknown. Transmission of COVID-19 could be airborne or human-to-human contact; however, both aerosol and fecal-oral transmission still remain unclear [13]. To date, critical public health measures to reduce the transmission of COVID-19 include quarantine both in community and clinicians, as well as timely diagnosis (through testing kits, etc.) and strict participation to prevent the spread of the virus in health care settings [16]. Furthermore, lessons from the influenza virus (H1N1, SARS-CoV, and MERS-CoV) outbreak also support to effectively prepare for COVID-19 outbreak [17].

Main Points

- Arylesterase (ARE) activity could be a useful marker in COPD.
- PON1 RR phenotype was common in COPD and this result is consistent with PON1 genotype studies in COPD.
- Smoking and RR phenotype can be defined independent determinants relation with COPD.

Wearing Masks to Prevent COVID-19 Infection

Influence of droplet travel in person-to-person transmission

As known, reducing transmission of the influenza virus in both community and clinicians may not only help support them but also prevent person-to-person transmission during an influenza virus pandemic. For other protective strategies, drugs or vaccines may be limited in

availability. Thus, it is truly necessary for clearly understanding the influence of droplet travel in person-to-person transmission to support the COVID-19 infection prevention. Transmission of COVID-19 could be airborne or through contact, especially large droplets and airborne routes are credited to person-to-person transmission, which could be the cause of a large number of influenza infections, as well as travel of droplets, which involves traveling of droplet-




Figure 1. a-d. Images of the thoracic CT scans of patients in a family and the multifocal ground-glass changes in the lungs of mother (a), father (b), daughter (c), and grandson (d) [Reprinted with permission from [14]]




Figure 2. Travel of droplets using Wells evaporation–falling curve. [Reprinted with permission from [37].

borne diseases that can transmit from one person to another. A typical example for travel of droplets is sneezing, which is seen as an exhalation mode with common respiratory symptoms; in particular, respiratory infectious symptoms could create mucus and stimulate various nerves within the nasal mucous membranes and lead to a sneeze. However, the mechanism of the biological dynamics of a sneeze is a little different from that of other respiratory activities. According to some references, the velocity of the exhaled air in sneezing is much larger than that of breathing and coughing [18-20], and the created total number of droplets during the sneeze is also larger than that of other respiratory activities [21]; one can refer to some references of the distribution of size of droplets produced by a cough [22-24], a sneeze [25-27], speech [24, 28, 29], and a breath [24, 30-33], and the concentration and number of droplets [34-36].

Using the Wells evaporation-falling curve (Figure 2) [37, 38], the transmission of droplets is considered to be on the basis of relative humidity, air speed, and respiratory jets, which could be the result of their evaporation and movement from expulsion during respiratory activities. Specifically, Xie et al. [37] calculated both lifetimes and size changes of a droplet, as well as how far the droplets travel. The results showed that the droplets with the largest size possible completely evaporate before falling 2 m away (60-100 μm); these droplets are moved further away by the exhaled air at a suitable velocity (n) (i.e., $>6\text{ m [}n=50\text{ ms}^{-1}\text{]}$ in sneezing, $>2\text{ m [}n=10\text{ ms}^{-1}\text{]}$ in coughing, and $<1\text{ m [}n=1\text{ ms}^{-1}\text{]}$ in breathing). It is really important to develop measures of effective engineering control for the prevention of respiratory infectious symptoms, as well as to explore the person-to-person transmission mechanisms involving travel of droplets of infectious diseases. The results suggested that the rapid evaporation of small droplets and the quick falling of larger droplets on the ground or on surfaces, as well as horizontally deported large droplets could also travel a long distance. Moreover, these droplets could be suspended in the air with low relative humidity conditions, which can lead to the increase in the possibility of subsequent inhalation. Thus, an understanding of the travel of droplets has been significant for developing measures of effective engineering control in the prevention of COVID-19 infection and in exploring the person-to-person transmission mechanisms of infectious diseases. However, respiratory protection demonstrates that aerial transmission is one of the assumed methods of transmission of the influenza virus [39]. The results of trials confirmed that only large droplets are discovered close to the pa-

tient, and small droplet nuclei and airborne particles are discovered at a longer distance [40-42]. Besides, the particles with small and large sizes could be found at short distances from the patient, and aerosolized transmission could also occur at a close distance [41].

Finally, the main transmission of COVID-19 is related to the droplets created when a person breathes, talks, coughs, or sneezes. When the droplets travel, they get suspended in the air and quickly fall on the ground or on surfaces. Besides, anyone can become infected with the virus because of breathing within 1 m of person-to-person distance as well as touching a contagious surface followed by touching eyes, nose, or mouth without washing hands.

Effect of Wearing Masks in COVID-19 Infection Prevention

There are some randomized controlled clinical trials (RCTs), which are not only based on handwashing [43-45] but also on wearing masks (cloth masks, medical masks, N95 respirators, and surgical masks) both in community and clinicians [46-49]; however, the trials of wearing masks for respiratory protection are limited, and the effect of wearing masks in the COVID-19 infection prevention is not yet clearly understood. As known, the influenza spread could occur by coughing or sneezing where infectious particles could be inhaled with a range of 0.1-100 μm [50-55]; thus, the personal respiratory protective equipment is really needed to prevent or limit the influenza virus outbreak. Besides, N95 respirators could be unavailable in many countries at short notice of a pandemic; therefore, it is truly important to understand clearly the relative effectiveness of personal respiratory protective equipment. So far, there are a few comparative studies of personal respiratory protective equipment [46,47] and data comparing the surgical mask with the N95 respirator among HCWs [56,57]. Although N95 respirators are not regularly suggested for seasonal influenza, they could play a role in personal protection against the influenza virus pandemic (H1N1, SARS, MERS, and COVID-19 viruses). The result indicates that HCWs wearing surgical masks are not prone to experience influenza compared with those wearing N95 respirators while treating patients with influenza. There are trials for personal protection against respiratory infections, for example, MacIntyre et al. [58] performed RCTs to investigate the effect of medical masks and N95 respirators, proving that N95 respirators provided superior protection against infections of droplet transmission. Besides, to ensure safety and health of HCWs, the superiority of respirators in preventing re-

spiratory infections are also included in infection control guidelines. Currently, there are only five published RCTs in HCWs, which leads to a lack of a common ground around the effect of two kinds of masks (medical masks and N95 respirators) for HCWs against influenza [48, 59-62]. Although N95 respirators have been displayed as superior than medical masks in preventing influenza respiratory infection, there are still no studies that examined the laboratory-confirmed influenza. In other smaller trials, it was found that there is no increase in respiratory diseases between HCWs while wearing medical masks [59]. Besides, there is only one small-scale RCT that compared medical masks and N95 respirators in HCWs [48], concluding that there is no difference, but there is a lack of an arm of controlling. Although medical masks were not designed to provide respiratory protection [63], with lower filtration efficiency, they were designed specifically for personal protection [64-66]. Moreover, they were designed to prevent wound contamination for the surgeon [67-69]. Thus, these large-scale RCTs were also unable to demonstrate any differences between the two kinds of masks in the influenza infection [60, 61]. A recently conducted trial identified the effect of cloth masks compared with medical masks, concluding that cloth masks could increase the risk of infection in HCWs [62]. In addition, the period of wearing the disposable mask, extent to which it protects, and invention of reusable masks should be researched further.

Overall, in the current COVID-19 outbreak, wearing suitable type of masks to prevent COVID-19 infection is truly necessary and limits the infection of the influenza virus. However, there are several important limitations of the RCTs, including the lack of performed measures during the study period and non-collection of data regarding the frequency of device changing [70]. If everyone wears masks, we cannot differentiate between those who are unwell by observing that they are wearing masks. Recently, the World Health Organization suggested that people with respiratory symptoms and those who care for people with symptoms should wear masks [71]. It is truly important to wear and remove masks correctly to reduce the person-to-person transmission of COVID-19 as well as to ensure correct fit of the mask so that it covers the nose and mouth properly [72, 73]. We should use soap with water (or warm water) or hand sanitizer for handwashing, and make sure that the mask covers the nose, mouth, and chin properly, and has adjustable ties to ensure that there are no gaps, and we should avoid touching or adjusting the masks during use. Similar measures are taken while removing a mask, with few

differences: untie the bottom tie of the mask, then remove top tie and remove the mask from the face; the mask must be discarded immediately and cannot be reused. Handwashing is the final step. Moreover, older adults and people with underlying medical conditions are recommended to wear masks, if available.

In summary, to develop effective measures of prevention to control infectious diseases in both community and clinicians, it is necessary to understand clearly the knowledge about prevention of the influenza virus. Because the COVID-19 pandemic is worsening by the hour, individuals need to rapidly respond to this risk. Washing hands diligently, covering coughs, and avoiding crowds and close contact are measures to avoid the risks of transmission in the community. Wearing masks routinely is especially recommended for all individuals to prevent exposure in the community before the vaccine is invented. Therefore, isolation, handwashing, and preventing the spread of the virus are the practical strategies used to tackle the spread of COVID-19. In addition, respiratory protection by wearing masks is one of the methods to prevent infection of the influenza virus; however, trials related to COVID-19 are limited. In addition, the period of wearing the disposable mask, the level of protection of masks, and the invention of reusable masks should be researched further.

Ethics Committee Approval: N/A.

Informed Consent: N/A.

Peer-review: Externally peer-reviewed.

Author Contributions: All authors have contributed to the writing of the manuscript. T.S. Vo and T.T.B.C. Vo designed the topic and wrote the manuscript. T.T.T.N. Vo and T.T.B.C. Vo edited the final manuscript. All authors read and approved the final manuscript.

Acknowledgements: The authors thank the regularly updated useful information, lectures and articles of scientists, as well as the support of Qui Nhon City Hospital.

Conflict of Interest: The authors declared no conflicts of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

References

- Horcajada JP, Pumarola T, Martinez JA, et al. A nosocomial outbreak of influenza during a period without influenza epidemic activity. *Eur Respir J* 2003; 21: 303-7. [\[Crossref\]](#)
- Dawood FS, Jain S, Finelli L, et al. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, New Engl J Med 2009; 360: 2605-15. [\[Crossref\]](#)
- Cohen J, Enserink M. SWINE FLU After Delays, WHO Agrees: The 2009 Pandemic Has Begun. *Science* 2009; 324: 1496-7. [\[Crossref\]](#)
- Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. *Nature* 2009; 459: 931-9. [\[Crossref\]](#)
- Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. *Lancet* 2003; 361: 1761-6. [\[Crossref\]](#)
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020; 38: 727-33. [\[Crossref\]](#)
- Lu HZ, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol* 2020; 92: 401-2. [\[Crossref\]](#)
- Hui DS, Azha EI, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020; 91: 264-6. [\[Crossref\]](#)
- Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 496. [\[Crossref\]](#)
- Su S, Wong G, Shi WF, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends Microbiol* 2016; 24: 490-502. [\[Crossref\]](#)
- Diagnosis and treatment of new coronavirus pneumonia (version 5)', National Health Commission of the People's Republic of China, 2020. Available From: URL: <http://www.nhc.gov.cn/>.
- Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med* 2020; 382: 872-4. [\[Crossref\]](#)
- Holshue ML. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* 2020; 382: 929-36. [\[Crossref\]](#)
- Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; 395: 514-23. [\[Crossref\]](#)
- Cohen, J. Wuhan seafood market may not be source of novel virus spreading globally', 2020. Available From: URL: <https://www.sciencemag.org/news/2020/2001/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> [\[Crossref\]](#)
- Carlos WG, Dela Cruz CS, Cao B, et al. Novel Wuhan (2019-nCoV) Coronavirus. *Am J Resp Crit Care* 2020; 201: 7-8. [\[Crossref\]](#)
- Yoo JH. The Fight against the 2019-nCoV Outbreak: an Arduous March Has Just Begun. *J Korean Med Sci* 2020; 35: e56. [\[Crossref\]](#)
- Gao NP, Ni JL. Transient CFD simulation of the respiration process and inter-person exposure assessment. *Build Environ* 2006; 41: 1214-22. [\[Crossref\]](#)
- Gupta JK, Lin CH, Chen Q. Flow dynamics and characterization of a cough', *Indoor Air* 2009; 19: 517-25. [\[Crossref\]](#)
- Gupta JK, Lin C, Chen QY. Characterizing exhaled airflow from breathing and talking. *Indoor Air* 2010; 20: 31-9. [\[Crossref\]](#)
- Duguid JP. The size and the duration of air-carriage of respiratory droplets and droplet-nuclei. *J Hyg* 1946; 44: 471-9. [\[Crossref\]](#)
- Fennelly KP, Martyny JW, Fulton KE, et al. Cough-generated aerosols of Mycobacterium tuberculosis - A new method to study infectiousness. *Am J Resp Crit Care* 2004; 169: 604-9. [\[Crossref\]](#)
- Yang SH, Lee GWM, Chen CM, et al. The size and concentration of droplets generated by coughing in human subjects. *J Aerosol Med* 2007; 20: 484-94. [\[Crossref\]](#)
- Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. *J Aerosol Med Pulm D* 2009; 22: 229-37. [\[Crossref\]](#)
- Buckland FE, Tyrrell DA. Experiments on spread of colds: I. Laboratory studies on dispersal of nasal secretion. *J Hyg* 1964; 62: 365-77. [\[Crossref\]](#)
- Nicas M, Nazaroff W, Hubbard A. Toward understanding the risk of secondary airborne infection: Emission of respirable pathogens. *J Occup Environ Hyg* 2005; 2: 143-54. [\[Crossref\]](#)
- Gratton J, Tovey E, McLaws ML, et al. The role of particle size in aerosolised pathogen transmission: A review. *J Infection* 2011; 62: 1-13. [\[Crossref\]](#)
- Chao CYH, Wan MP, Morawska L, et al. Characterization of expiration air jets and droplet size distributions immediately at the mouth opening. *J Aerosol Sci* 2009; 40: 122-33. [\[Crossref\]](#)
- Xie XJ, Li YG, Sun HQ, et al. Exhaled droplets due to talking and coughing. *J R Soc Interface* 2009; 6: S703-14. [\[Crossref\]](#)
- Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols. *P Natl Acad Sci USA* 200; 101: 17383-8. [\[Crossref\]](#)
- Fabian P, McDevitt JJ, DeHaan WH, et al. Influenza Virus in Human Exhaled Breath: An Observational Study. *Plos One* 2008; 3: e2691. [\[Crossref\]](#)
- Wainwright CE, France MW, O'Rourke P, et al. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. *Thorax* 2009; 64: 926-31. [\[Crossref\]](#)
- Almstrand AC, Bake B, Ljungstrom E, et al. Effect of airway opening on production of exhaled particles. *J Appl Physiol* 2010; 108: 584-8. [\[Crossref\]](#)
- Haslbeck K, Schwarz K, Hohfeld JM, et al. Sub-micron droplet formation in the human lung. *J Aerosol Sci* 2010; 41: 429-38. [\[Crossref\]](#)
- Holmgren H, Ljungstrom E, Almstrand AC, et al. Size distribution of exhaled particles in the range from 0.01 to 2.0 µm. *J Aerosol Sci* 2010; 41: 439-46. [\[Crossref\]](#)
- Morawska L, Johnson GR, Ristovski ZD, et al. Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities. *J Aerosol Sci* 2009; 40: 256-69. [\[Crossref\]](#)

37. Fabian P, Brain J, Houseman EA, et al. Origin of exhaled breath particles from healthy and human rhinovirus-infected subjects. *J Aerosol Med Pulm D* 2011; 24: 137-47. [\[Crossref\]](#)
38. Xie X, Li Y, Chwang ATY, et al. How far droplets can move in indoor environments - revisiting the Wells evaporation-falling curve *Indoor Air* 2007; 17: 211-25. [\[Crossref\]](#)
39. Wells WF. On air-borne infection: Study II. Droplets and droplet nuclei. *Am J Hyg* 1934; 20: 611-8. [\[Crossref\]](#)
40. MacIntyre CR, Chughtai AA, Seale H, et al. Respiratory protection for healthcare workers treating Ebola virus disease (EVD): Are face-masks sufficient to meet occupational health and safety obligations?. *Int J Nurs Stud* 2014; 51: 1421-6. [\[Crossref\]](#)
41. Osterholm MT, Moore KA, Kelley NS, et al. Transmission of Ebola Viruses: What we know and what we do not know. *mBio* 2015; 6: e01154. [\[Crossref\]](#)
42. Shuchman M. Improving protection for Ebola workers. *Can Med Assoc J* 2015; 187: E85-6. [\[Crossref\]](#)
43. Delamou A, Beavogui AH, Konde MK, et al. Ebola: better protection needed for Guinean health-care workers. *Lancet* 2015; 385: 503-4. [\[Crossref\]](#)
44. Perez-Garza J, Garcia S, Heredia N. Removal of *Escherichia coli* and *Enterococcus faecalis* after hand washing with antimicrobial and nonantimicrobial soap and persistence of these bacteria in rinsates. *J Food Protect* 2017; 80: 1670-5. [\[Crossref\]](#)
45. Larson EL, Lin SX, Gomez-Pichardo C, et al. Effect of antibacterial home cleaning and hand-washing products on infectious disease symptoms - A randomized, double-blind trial. *Ann Intern Med* 2004; 140: 321-9. [\[Crossref\]](#)
46. Rabie T, Curti V. Handwashing and risk of respiratory infections: a quantitative systematic review. *Trop Med Int Health* 2006; 11: 258-67. [\[Crossref\]](#)
47. Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and Hand Hygiene to Prevent Influenza Transmission in Households A Cluster Randomized Trial. *Ann Intern Med* 2009; 151: 437-W144. [\[Crossref\]](#)
48. MacIntyre CR, Cauchemez S, Dwyer DE, et al. Face Mask Use and Control of Respiratory Virus Transmission in Households *Emerg Infect Dis* 2009; 15: 233-41. [\[Crossref\]](#)
49. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing Influenza among health care workers a randomized trial. *JAMA* 2009; 302: 1865-71. [\[Crossref\]](#)
50. Atrie D, Worster A. Surgical mask versus N95 respirator for preventing influenza among health care workers: a randomized trial. *Can J Emerg Med* 2012; 14: 50-2. [\[Crossref\]](#)
51. Maines TR, Jayarama A, Belser JA, et al. Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and Mice. *Science* 2009; 325: 484-7. [\[Crossref\]](#)
52. Tellier R. Transmission of influenza A in human beings. *Lancet Infect Dis* 2007; 7: 759-60. [\[Crossref\]](#)
53. Lee RV. Transmission of influenza A in human beings. *Lancet Infect Dis* 2007; 7: 760-1. [\[Crossref\]](#)
54. Tang JW, Li G. Transmission of influenza A in human beings. *Lancet Infect Dis* 2007; 7: 758. [\[Crossref\]](#)
55. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. *Lancet Infect Dis* 2007; 7: 257-65. [\[Crossref\]](#)
56. Naik AD, Issac TT, Street RL, et al. Understanding the quality chasm for hypertension control in diabetes: A structured review of "Co-manuevers" used in clinical trials. *J Am Board Fam Med* 2007; 20: 469-78. [\[Crossref\]](#)
57. Roland M, Torgerson DJ. Clinical review: understanding controlled trials: what are pragmatic trials?. *BMJ* 1998; 316: 285. [\[Crossref\]](#)
58. MacIntyre CR, Chughtai AA, Rahma B, et al. The efficacy of medical masks and respirators against respiratory infection in healthcare workers. *Influenza Other Resp* 2017; 11: 511-7. [\[Crossref\]](#)
59. Jacobs JL, Ohde S, Takahashi O, et al. Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: A randomized controlled trial. *Am J Infect Control* 2009; 37: 417-9. [\[Crossref\]](#)
60. MacIntyre CR, Wang QY, Cauchemez S, et al. A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. *Influenza Other Resp* 2011; 5: 170-9. [\[Crossref\]](#)
61. MacIntyre CR, Wang QY, Seale H, et al. A Randomized Clinical Trial of Three Options for N95 Respirators and Medical Masks in Health Workers. *Am J Resp Crit Care* 2013; 187: 960-6. [\[Crossref\]](#)
62. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. *BMJ Open* 2015; 5: e006577. [\[Crossref\]](#)
63. Shine KI, Rogers B, Goldfrank LR. Novel H1N1 Influenza and Respiratory Protection for Health Care Workers. *New Engl J Med* 2009; 361: 1823-5. [\[Crossref\]](#)
64. Balazy A, Toivola M, Adhikari A, et al. Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? *Am J Infect Control* 2006; 34: 51-7. [\[Crossref\]](#)
65. Lawrence RB, Duling MG, Calvert CA, et al. Comparison of performance of three different types of respiratory protection devices. *J Occup Environ Hyg* 2006; 3: 465-74. [\[Crossref\]](#)
66. Weber A, Willeke K, Marchioni R, et al. Aerosol penetration and leakage characteristics of masks used in the health-care industry. *Am J Infect Control* 1993; 21: 167-73. [\[Crossref\]](#)
67. Sellden E. Is routine use of a face mask necessary in the operating room? *Anesthesiology* 2010; 113: 1447. [\[Crossref\]](#)
68. Mitchell NJ, Hunt S. Surgical face masks in modern operating-rooms - a costly and unnecessary ritual. *J Hosp Infect* 1991; 18: 239-42. [\[Crossref\]](#)
69. Tunevall TG, Bessey PQ. Postoperative wound infections and surgical face masks - a controlled-study. *World J Surg* 1991; 15: 383-8. [\[Crossref\]](#)
70. Palen TE, Felix KG. Surgical masks vs N95 respirators for preventing influenza. *JAMA* 2010; 303: 937. [\[Crossref\]](#)
71. Feng S, Shen C, Xia N, et al. Rational use of face masks in the COVID-19 pandemic. *Lancet Respir Med* 2020; 8: 434-6. [\[Crossref\]](#)
72. Does Wearing a Mask Protect You from the Flu and Other Viruses? Healthline, 2020. Available From: URL: <https://www.healthline.com/health/cold-flu/mask>
73. COVID-19 (novel coronavirus) - face mask and hygiene advice. Ministry of Health Manatū Hauora, 2020. Available From: URL: <https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-novel-coronavirus-health-advice-general-public/covid-19-novel-coronavirus-face-mask-and-hygiene-advice>